Stem Cell Therapy Is a Promising Tool for Refractory Angina: A Meta-analysis of Randomized Controlled Trials

2013 ◽  
Vol 29 (8) ◽  
pp. 908-914 ◽  
Author(s):  
Na Li ◽  
Yue-Jin Yang ◽  
Qian Zhang ◽  
Chen Jin ◽  
Hong Wang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Randomized Controlled Trials ◽  
Stem Cell Therapy ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Refractory Angina ◽  
Randomized Controlled ◽  
Promising Tool

scholarly journals The Impact of Cell Therapy on Cardiovascular Outcomes in Patients With Refractory Angina

2019 ◽  
Vol 124 (12) ◽  
pp. 1786-1795 ◽  
Author(s):  
Daniel A. Jones ◽  
Deshan Weeraman ◽  
Martina Colicchia ◽  
Mohsin A. Hussain ◽  
Devanayegi Veerapen ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Randomized Controlled Trials ◽  
Odds Ratio ◽  
Exercise Tolerance ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Refractory Angina ◽  
Canadian Cardiovascular Society ◽  
Randomized Controlled ◽  
Canadian Cardiovascular Society Class

Rationale: Cell-based therapies are a novel potential treatment for refractory angina and have been found to improve markers of angina. However, the effects on mortality and major adverse cardiac events (MACE) have not been definitively investigated. Objective: To investigate the efficacy and safety of stem cell treatment compared with optimal medical treatment for refractory angina by conducting an updated meta-analysis, looking at clinical outcomes. Methods and Results: We performed a systematic review and meta-analysis of randomized controlled trials using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. A comprehensive search was performed of PubMed, EMBASE (Excerpta Medica database), Cochrane, ClinicalTrials.gov , Google Scholar databases of randomized controlled trials, and scientific session abstracts. Studies were deemed eligible if they met the following criteria: (1) full-length publications in peer-reviewed journals; (2) evaluated cell therapy use in patients with no further revascularisation options while on optimal medical treatment; (3) patients had ongoing angina, Canadian Cardiovascular Society class II—IV; and (4) included a placebo/control arm. We calculated risk ratios for all-cause mortality, combined MACE events. We assessed heterogeneity using χ 2 and I 2 tests. We identified 1191 citations with 8 randomized controlled trials meeting inclusion criteria involving 526 patients. Outcomes pooled were MACE, mortality, and indices of angina (angina episodes, Canadian Cardiovascular Society angina class, exercise tolerance, and antianginal medications). Our analysis showed a decreased risk of both MACE (odds ratio, 0.41; CI, 0.25−0.70) and mortality (odds ratio, 0.24; 95% CI, 0.10−0.60) in cell-treated patients compared with patients on maximal medical therapy. This was supported by improvements in surrogate end points of anginal episodes, use of antianginal medications, Canadian Cardiovascular Society class, and exercise tolerance. Conclusions: In addition to improvements in indices of angina, cell-based therapies improve cardiovascular outcomes (mortality/MACE) in patients with refractory angina. Given the premature termination of the phase III study, this supports the need for further definitive trials. Prospero Registration : URL: https://www.crd.york.ac.uk/prospero/ . Unique identifier: CRD42018084257.

scholarly journals Autologous Stem Cell Therapy for Chronic Lower Extremity Wounds: A Meta-Analysis of Randomized Controlled Trials

Cells ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 3307
Author(s):  
Kuan-Ju Chiang ◽  
Li-Cheng Chiu ◽  
Yi-No Kang ◽  
Chiehfeng Chen
Keyword(s):  
Wound Healing ◽  
Stem Cell ◽  
Cell Therapy ◽  
Lower Extremity ◽  
Randomized Controlled Trials ◽  
Stem Cell Therapy ◽  
Healing Rate ◽  
Complete Healing ◽  
Controlled Trials ◽  
Randomized Controlled

Lower extremity chronic wounds (LECWs) commonly occur in patients with diabetes mellitus (DM) and peripheral arterial disease (PAD). Autologous stem cell therapy (ASCT) has emerged as a promising alternative treatment for those who suffered from LECWs. The purpose of this study was to assess the effects of ASCT on LECWs. Two authors searched three core databases, and independently identified evidence according to predefined criteria. They also individually assessed the quality of the included randomized controlled trials (RCTs), and extracted data on complete healing rate, amputation rate, and outcomes regarding peripheral circulation. The extracted data were pooled using a random-effects model due to clinical heterogeneity among the included RCTs. A subgroup analysis was further performed according to etiology, source of stem cells, follow-up time, and cell markers. A total of 28 RCTs (n = 1096) were eligible for this study. The pooled results showed that patients receiving ASCT had significantly higher complete healing rates (risk ratio (RR) = 1.67, 95% confidence interval (CI) 1.28–2.19) as compared with those without ASCT. In the CD34+ subgroup, ASCT significantly led to a higher complete healing rate (RR = 2.70, 95% CI 1.50–4.86), but there was no significant difference in the CD34− subgroup. ASCT through intramuscular injection can significantly improve wound healing in patients with LECWs caused by either DM or critical limb ischemia. Lastly, CD34+ is an important cell marker for potential wound healing. However, more extensive scale and well-designed studies are necessary to explore the details of ASCT and chronic wound healing.

Intramyocardial autologous CD34+ cell therapy for refractory angina: A meta-analysis of randomized controlled trials

2019 ◽  
Vol 20 (3) ◽  
pp. 215-219 ◽  
Author(s):  
Poonam Velagapudi ◽  
Mohit Turagam ◽  
Dhaval Kolte ◽  
Sahil Khera ◽  
Omar Hyder ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Refractory Angina ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document